Ozerdem U, Mach-Hofacre B, Keefe K, Pham T, Soules K, Appelt K, Freeman W R
Shiley Eye Center, University of California, San Diego, CA 92093-0946, USA.
Ophthalmic Res. 2001 Jan-Feb;33(1):20-3. doi: 10.1159/000055636.
In a search for a pharmacologic adjuvant in the management of posttraumatic proliferative vitreoretinopathy (PVR), we investigated the effect of intravitreal injection of prinomastat (AG3340) on an experimental model. Posterior penetrating eye trauma was created in one eye each of 24 New Zealand white rabbits. One week after the surgery, all rabbits were randomized (1:1) to receive 0.5 mg prinomastat or the vehicle of the drug intravitreally every week for 6 weeks. The degree of PVR for each hemiretina was scored, and the two scores were summed to obtain a total eye score. The mean total eye score was 3.58 in the treatment group and 5.75 in the control group (p = 0.0307). The numbers of eyes with tractional retinal detachment in the prinomastat-treated (n = 12) and control (n = 12) groups were 3 and 9, respectively (p = 0.0391). These results suggest that intravitreally administered prinomastat has an inhibitory effect on posttraumatic PVR.
为了寻找创伤后增殖性玻璃体视网膜病变（PVR）治疗中的药物辅助剂，我们研究了玻璃体内注射普林司他（AG3340）对实验模型的影响。在24只新西兰白兔的每只眼睛上造成后段穿通性眼外伤。手术后一周，将所有兔子随机（1:1）分为两组，一组每周玻璃体内注射0.5mg普林司他，另一组注射药物赋形剂，共持续6周。对每个半视网膜的PVR程度进行评分，将两个评分相加得到全眼总分。治疗组的平均全眼总分为3.58，对照组为5.75（p = 0.0307）。普林司他治疗组（n = 12）和对照组（n = 12）中发生牵拉性视网膜脱离的眼数分别为3只和9只（p = 0.0391）。这些结果表明，玻璃体内注射普林司他对创伤后PVR有抑制作用。
